© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
May 18th 2021, 8:40pm
A series of 5 cases highlights different opportunities to incorporate selexipag into the care of patients with pulmonary arterial hypertension, potentially eliminating risks associated with parenteral prostacyclin.
May 13th 2021, 10:30am
Right ventricular end-systolic elastance to end-systolic arterial elastance coupling in excess of 0.68 was linked with preserved right ventricular function and better survival outcomes in patients with heart failure with reduced ejection fraction and secondary pulmonary hypertension.
May 7th 2021, 6:35pm
In a first-of-its kind study, young children undergoing heart surgery had similar results regardless of whether they received levosimendan intravenously or via inhalation.
April 30th 2021, 1:00pm
Patients with pulmonary arterial hypertension (PAH) who have comorbidities or advanced age who are treated with a monotherapy have comparable outcomes to patients on combination therapies.
April 27th 2021, 1:30pm
A text message–based intervention successfully increased step counts for patients with pulmonary arterial hypertension (PAH).
April 21st 2021, 1:30pm
While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.
April 18th 2021, 1:15pm
An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.
April 15th 2021, 1:45pm
New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).
April 13th 2021, 4:25pm
A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
April 6th 2021, 9:28pm
Adjunct nutritional therapies may be a simple way to improve the prognosis for patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension who are hospitalized.